Tirzepatide: 15mg*10vials/box

Description

Usage: All products on this site are for In-Vitro Research, Development use only. Products are Not for Human consumption of any kind.

Data

Name: Tirzepatide

CAS No.: 2023788-19-2

PubChem CID: 156588324

IUPHAR/BPS: 11429

DrugBank: DB15171

ChemSpider: 76714503

UNII: OYN3CCI6QE

KEGG: D11360

ChEMBL: ChEMBL4297839

Formula: C225H348N48O68

Molar mass: 4813.527 g·mol−1

Other Names: LY3298176, GIP/GLP-1 RA

Purity: 98.5%min

Brand Name: UNEWLIFE

Grade: Pharm Medicine Grade

MFG: each batch fresh in 2023

Shelf Life: 2 years of proper storage

Appearance: White Powder

Test Reports: MS/COA/HPLC

Packing: 15mg*10vials/box

Label: without labels, can be OEM/ODM customized.

Box: white carton box, that can be OEM/ODM customized.

Shipping: by express or post.

Feedback: How do they say? More reviews here

For more questions, check the answers here: FAQ 

Description

Tirzepatide is a first-in-class medication that activates both the GLP-1 and GIP receptors, which leads to improved blood sugar control.
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in blood sugar control.

Tirzepatide is indicated to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.

 

Mechanism of action

Tirzepatide is an analogue of gastric inhibitory polypeptide (GIP), a human hormone that stimulates the release of insulin from the pancreas. Tirzepatide is a linear polypeptide of 39 amino acids that has been chemically modified by lipidation to improve its uptake into cells and its stability to metabolism. It completed phase III trials globally in 2021.

Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies have shown that this is due to tirzepatide mimicking the actions of natural GIP at the GIP receptor. However, at the GLP-1 receptor, tirzepatide shows bias towards cAMP (a messenger associated with regulation of glycogen, sugar and lipid metabolism) generation, rather than β-arrestin recruitment. This combination of preference towards GIP receptor and distinct signaling properties at GLP-1 suggest this biased agonism increases insulin secretion.
Tirzepatide has also been shown to increase levels of adiponectin, an adipokine involved in the regulation of both glucose and lipid metabolism, with a maximum increase of 26% from baseline after 26 weeks, at the 10 mg dosage.

 

 

Resaerch progress

Lilly’s tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1

 

FAQ on Tirzepatide

 

• Is tirzepatide available?

In May 2022, the FDA approved tirzepatide (Mounjaro) for adults living with Type 2 diabetes. It’s the first in a new class of medications. Tirzepatide is a once-weekly injection that comes in six different strengths.

 

• What type of drug is tirzepatide?

Tirzepatide is the first drug in a new class of diabetes medications. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. GLP-1 and GIP are gut hormones called incretins, and the intestines release them when we eat.

 

• How does tirzepatide work for weight loss?

The trial participants lost up to a fifth of their body weight on average, compared with 3% in the placebo group. Tirzepatide works by mimicking two hormones that help people feel full after eating.

 

• What is tirzepatide brand name?

Tirzepatide, sold under the brand name Mounjaro, is a medication used for the treatment of type 2 diabetes. Tirzepatide is given by subcutaneous injection (under the skin). Common side effects may include nausea, vomiting, diarrhea, constipation, upper abdominal discomfort, and abdominal pain.

 

• Is tirzepatide better than Semaglutide?

At all doses, tirzepatide was superior to semaglutide.

 

• What is the newest treatment for type 2 diabetes?

A new drug to treat type 2 diabetes has received approval from federal regulators. The drug tirzepatide is a once-a-week injection that helps people manage blood glucose levels and reduce food intake.

 

• What is tirzepatide used for?

Today, the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.

 

• How much does tirzepatide cost?

Tirzepatide’s Retail Price Set at About $12,666 Per Year.

 

• How is tirzepatide given?

Tirzepatide administered SC to healthy participants via a prefilled syringe (PFS) in one of two study periods. Inclusion Criteria: Healthy males or females of nonchildbearing potential as determined by medical history, physical examination, and other screening procedures.

 

• What is the diabetes drug that helps with weight loss?

A drug approved to treat Type 2 diabetes is extremely effective at reducing obesity, according to a new study. The drug, called tirzepatide, works on two naturally occurring hormones that help control blood sugar and are involved in sending fullness signals from the gut to the brain.

 

• Who manufactures Tirzepatide?

Tirzepatide is an acylated long-acting dual glucose-dependent insulinotropic peptide (GIP) and a glucagon-like-peptide 1 (GLP-1) receptor agonist, being developed by Eli Lilly and Company, for the treatment of type 2 diabetes mellitus, heart failure with preserved ejection fraction (HFpEF), obesity, non-alcoholic.

 

• What is Tirzepatide made of?

Tirzepatide combines a GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist in a single novel molecule. The drug is administered once-weekly by sub-cutaneous injection.

 

• Is Tirzepatide the same as Semaglutide?

Tirzepatide was significantly better than semaglutide at lowering HbA1c and body weight. The mean decrease in HbA1c was −2.01 percentage points, −2.24 percentage points, and −2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively versus. −1.86 percentage points with semaglutide.

 

• Is Tirzepatide once weekly?

Tirzepatide Once Weekly for the Treatment of Obesity.

 

• Is Tirzepatide available in Australia?

Tirzepatide is an experimental treatment. This means that it is not an approved treatment for type 2 diabetes in Australia.

 

• What is the safest type 2 diabetes medication?

Most experts consider metformin to be the safest medicine for type 2 diabetes because it has been used for many decades, is effective, affordable, and safe. Metformin is recommended as a first-line treatment for type 2 diabetes by the American Diabetes Association (ADA).

 

• Will there be a cure for type 2 diabetes in the future?

There’s no cure yet, but our scientists are working on a ground-breaking weight management study, to help people put their type 2 diabetes into remission. Remission is when blood glucose (or blood sugar) levels are in a normal range again.

 

• Does Tirzepatide have side effects?

What is clear now is the most common side effects of tirzepatide are nausea and diarrhea, and people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not take tirzepatide.

 

• What is the new drug to fight obesity?

Semaglutide is the first of a new generation of highly effective hormone-based obesity medications. Semaglutide mimics a hormone called glucagon-like peptide-1 (GLP-1), which is secreted in the gut and targets receptors throughout the body, including the brain.

 

• Can you buy Tirzepatide?

Tirzepatide is a prescription-only medication, so you can’t buy it directly. Instead, you’ll need a prescription from an appropriate medical professional.

 

• What is the difference between Semaglutide and liraglutide?

Semglutide is a once weekly injection. Liraglutide 3mg(Saxenda®) injection has to be given every day. This because Semaglutide has a longer duration of action in the body. Research shows that Semaglutide is more effective in improving blood glucose control and weight loss compared to Liraglutide.

 

• What is tirzepatide made of?

Tirzepatide combines a GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist in a single novel molecule.

 

• What is the difference between Tirzepatide and Semaglutide?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) that was recently approved by the FDA for the treatment of type 2 diabetes. The drug is manufactured by Eli Lilly & Co. under the brand name Mounjaro™ and was approved in May 2022.

Semaglutide, on the other hand, is a glucagon-like peptide-1 receptor agonist, or GLP-1, drug that’s available under multiple brand names including Ozempic®, Wegovy®, and Rybelsus®. All three of these are made by Danish pharmaceutical company Novo Nordisk. Ozempic® and Rybelsus® are indicated for type 2 diabetes, whereas Wegovy® is specifically indicated for the treatment of overweight and obesity.

Both drugs show promise not only in improving metabolic health, reducing hemaglobin A1C (hbA1C), and assisting with weight loss—the data also shows that they may reduce the likelihood of cardiovascular events such as heart attack or stroke and improve cardiovascular outcomes across the board.

The below chart outlines some of the key similarities and differences between once-weekly tirzepatide and injectable semaglutide. Of the three brands, Ozempic® has been in use the longest.